MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, MEK inhibition with PD184352 combined with treatment with the farnesyltransferase inhibitor BMS-2144662 increases apoptosis in TKI-resistant CD34+ CML cells33.